Get the Stockscreener App
1.26
9.57%
0.11
After Hours:
1.15
-0.11
-8.73%
Cns Pharmaceuticals Inc stock is traded at $1.26, with a volume of 539.95K.
It is up +9.57% in the last 24 hours and up +31.66% over the past month.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
See More
Previous Close:
$1.15
Open:
$1.1
24h Volume:
539.95K
Relative Volume:
0.29
Market Cap:
$3.30M
Revenue:
-
Net Income/Loss:
$-17.06M
P/E Ratio:
-0.0178
EPS:
-70.7173
Net Cash Flow:
$-14.18M
1W Performance:
+12.50%
1M Performance:
+31.66%
6M Performance:
-76.02%
1Y Performance:
-99.75%
1-Day Range:
$1.10
$1.26
1-Week Range:
$1.06
$2.8999
52-Week Range:
$0.7715
$800.00
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
1.26 | 3.30M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.38 | 110.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.99 | 59.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
561.75 | 34.75B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.40 | 33.69B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
225.77 | 25.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
CNS Pharmaceuticals Raises $5M in Public Offering - TipRanks
CNS Pharmaceuticals (NASDAQ: CNSP) Prices $5 Million Public Offering with Institutional Investor - The Globe and Mail
Health Care Stocks Face Broad Downturn As Sector Challenges Mount - Finimize
CNS Pharmaceuticals sets terms for $5 million stock offering By Investing.com - Investing.com Nigeria
CNS Pharmaceuticals (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications - The Globe and Mail
CNS Pharmaceuticals Soars Over 100% on $5 Million Offering: What’s Driving the Surge? - RagingBull
CNS Pharmaceuticals sets terms for $5 million stock offering - Investing.com
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offer - GuruFocus
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - Stock Titan
CNSP Gains Key Orphan Drug Designation Transfer for TPI 287 | CN - GuruFocus
CNS Pharmaceuticals Acquires Orphan Drug Designation for TPI 287 in Glioblastoma - marketscreener.com
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, - GuruFocus
CNS Pharmaceuticals secures orphan drug status for cancer drug - Investing.com Australia
CNS Pharmaceuticals secures orphan drug status for cancer drug By Investing.com - Investing.com Nigeria
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 - Yahoo Finance
CNS Pharma Stock Price, Quotes and Forecasts | NASDAQ:CNSP - Benzinga
Medical Patent Injunction At Odds With Hatch-Waxman, Federal Circuit Finds - Law360
Press Release Distribution & PR Platform - ACCESS Newswire
CNSP stock touches 52-week low at $0.09 amid sharp decline - MSN
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
CNS Pharmaceuticals Advances TPI 287 for Glioblastoma - TipRanks
CNS Pharmaceuticals to Report Fourth Quarter 2019 Financial Results on March 12, 2020 - BioSpace
Financial Survey: KalVista Pharmaceuticals (NASDAQ:KALV) and CNS Pharmaceuticals (NASDAQ:CNSP) - Defense World
Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results - streetwisereports.com
CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year - Yahoo Finance
CNS Pharmaceuticals Reports Full Year 2024 Financial Results - Yahoo Finance
CNS Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
CNS Pharma's Strategic Shift: New Cancer Drug Focus as Losses Shrink 21% - Stock Titan
CNS Pharmaceuticals Inc. (CNSP) reports earnings - qz.com
CNS Pharmaceuticals (NASDAQ:CNSP) Receives Hold Rating from Maxim Group - Defense World
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): When Will It Breakeven? - Yahoo Finance
Market Sentiment Around Loss-Making CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) - simplywall.st
CNSP stock touches 52-week low at $1.49 amid sharp annual decline By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects - AInvest
Nasdaq Gains 50 Points; US New Home Sales Rise In February - Benzinga
CNSP stock touches 52-week low at $1.49 amid sharp annual decline - Investing.com
CNS Pharmaceuticals shares tumble after clinical trial results By Investing.com - Investing.com South Africa
CNS Pharmaceuticals shares tumble after clinical trial results - Investing.com India
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme - Yahoo Finance
Nasdaq Gains 50 Points, US New Home Sales Rise In February - Benzinga
CNS Pharmaceuticals expands stock sale agreement to $43.5 million - Investing.com
CNS Pharmaceuticals expands stock sale agreement to $43.5 million By Investing.com - Investing.com UK
The International Society for CNS Drug Development (ISCDD) Honors Sharon Mates, PhD, and Steven Paul, MD with Prestigious Leadership Award at 23rd Annual Meeting - Yahoo Finance
Plus Therapeutics Scores FDA Recognition for REYOBIQ Cancer DrugMajor Milestone for CNS Treatment - Stock Titan
Central Nervous System (CNS) Therapeutics Market to Reach USD - openPR
CNS Treatment and Therapy Market Size, Trends & Growth 2025-2035 - Future Market Insights
Houston’s Life Sciences Scene Continues Boosting Its Reputation - BioSpace
Xenon Pharmaceuticals Reveals Latest Progress on Revolutionary CNS Drug Development - Stock Titan
Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum - Business Wire
Cns Pharmaceuticals Inc to Host Earnings Call - ACCESS Newswire
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):